EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Hyoscine-n-butylbromide in treating abdominal pain caused by gastroenteritis: a double-blind randomized placebo controlled study

Çağdaş Yildirim iD, Gül Pamukçu Günaydin iD

Turkish Journal of Medical Sciences · 18.10.2024 · 54 (5) · 887-892

DOI: 10.55730/1300-0144.5864 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 18.10.2024. Verfasst von Çağdaş Yildirim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkiye. Hauptthemen laut MEDLINE: Butylscopolammonium Bromide, Abdominal Pain, Gastroenteritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/aimHyoscine-N-Butylbromide (HBB) is an anticholinergic agent widely used to treat pain caused by spasms in the gastrointestinal and urogenital systems. The aim of this study was to compare the efficacy of HBB with placebo in treating abdominal cramping pain caused by acute gastroenteritis in the Emergency Department (ED).Materials and methodsThis was a prospective, double-blind, placebo-controlled, randomized trial conducted in a single-center academic ED, from September to November 2021. Patients aged 18-65 years with acute gastroenteritis symptoms included in the study. The study compared the efficacy of intravenous HBB (20 mg) with placebo. The primary outcome was the absolute change in pain score at 30 minutes post-treatment, with secondary outcomes including pain relief at 60 minutes, adverse events, and the need for rescue analgesics.ResultsFifty patients were randomized (25 in each group). There was no significant difference between the groups in 30-minute and 60-minute pain scores. At 60 minutes, pain reduction and need for rescue analgesia were similar in both groups. Changes in pain scores from admission to 30 and 60 minutes did not significantly differ between groups.ConclusionIntravenous HBB, did not show a statistically or clinically significant difference in pain reduction compared to placebo in patients with acute gastroenteritis and cramping abdominal pain in the ED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Butylscopolammonium BromideAbdominal PainGastroenteritisHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultProspective StudiesAgedYoung AdultAdolescentPain MeasurementTreatment OutcomeEmergency Service, Hospital

Stichwörter der Autor:innen

Butylscopolammonium bromideabdominal paingastroenteritispain management

Substanzen

Butylscopolammonium Bromide

Autor:innen und Institutionen

  • Department of Emergency Medicine, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkiye.
  • Department of Emergency Medicine, Ankara Bilkent City Hospital, Ankara, Turkiye.

ORCID-Profile: Çağdaş Yildirim, Gül Pamukçu Günaydin

Zitieren

APA

Yildirim, Ç., & Pamukçu Günaydin, G. (2024). Hyoscine-n-butylbromide in treating abdominal pain caused by gastroenteritis: a double-blind randomized placebo controlled study. Turkish Journal of Medical Sciences, 54(5), 887-892. https://doi.org/10.55730/1300-0144.5864

Vancouver

Yildirim Ç, Pamukçu Günaydin G. Hyoscine-n-butylbromide in treating abdominal pain caused by gastroenteritis: a double-blind randomized placebo controlled study. Turkish Journal of Medical Sciences. 2024;54(5):887-892. doi:10.55730/1300-0144.5864

BibTeX
@article{Yildirim2024,
  author = {Yildirim, Çağdaş and Pamukçu Günaydin, Gül},
  title = {Hyoscine-n-butylbromide in treating abdominal pain caused by gastroenteritis: a double-blind randomized placebo controlled study},
  journal = {Turkish Journal of Medical Sciences},
  year = {2024},
  volume = {54},
  number = {5},
  pages = {887--892},
  doi = {10.55730/1300-0144.5864}
}
Kostenlos starten →